Abstract: Expandable branching stent prostheses and methods of deployment for the same are discussed herein. An expandable branching stent prosthesis may include a trunk portion, a first branching portion, and a second branching portion that are for deployment at, respectively, a trunk, a first branch, and a second branch of a branching implant site of an anatomical system. Methods for deploying the expandable branching stent prostheses include delivering a deployment system including the expandable branding stent prostheses, a balloon, a distal end of a floss wire, and in some cases a sock to the branching implant site; connecting, to the floss wire, a distal end of a snare wire delivered to the branching implant site via the second branch, and using the two floss wires to manipulate the deployment system to effectuate the deployment. In some cases, the sock may be pulled down over the balloon after the deployment.

Abstract: A balloon expandable branching stent prosthesis are discussed herein. The balloon expandable branching stent prosthesis includes a trunk portion including a trunk portion stent frame, a first branching portion including a first branching portion stent frame, a second branching portion including a second branching portion stent frame, and a cover coupling the trunk portion stent frame, the first branching stent frame, and the second branching stent frame together forming a bifurcated stent, wherein the trunk portion stent frame, the first branching portion stent frame, and the second branching portion stent frame are spaced apart from each other with the cover disposed therebetween. A crotch portion of the balloon expandable branching stent prosthesis is disposed between the trunk portion, the first branching portion, and the second branching portion and the crotch portion is reinforced to prevent radial infolding of the cover.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: A method and composition for preventing, reducing, or treating steroid-induced ocular hypertension and steroid-induced glaucoma using a selective Grp94 inhibitor is presented. The Grp94-selective inhibitor can include methyl 2-(2-(1(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (4-Br—BnIm) or a derivative thereof. The Grp94-selective inhibitor can be administered prior to, during, or after administration of a steroid to the patient.

Abstract: The disclosure provides methods of using inhibitors of chaperone proteins, such as HSP90 inhibitors, in combination with agents that increase proteotoxic stress on tumor cells or agents that induce a biochemical rewiring of the chaperome. The proteotoxic agents are administered prior to administration of the chaperone proteins to achieve synergistic activity.